Melittin, a honeybee venom derived peptide for the treatment of chemotherapy‑induced peripheral neuropathy

Tender, Tenzin and Rahangdale, Rakesh Ravishankar and Balireddy, Sridevi and Nampoothiri, Madhavan and Hariharapura, Raghu Chandrashekar (2021) Melittin, a honeybee venom derived peptide for the treatment of chemotherapy‑induced peripheral neuropathy. Medical Oncology, 38. pp. 1-9. ISSN 1357-0560

[img] PDF
12567.pdf - Published Version
Restricted to Registered users only

Download (1MB) | Request a copy

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is the most prevalent neurological complication of cancer treatment which involves sensory and motor nerve dysfunction. Severe CIPN has been reported in around 5% of patients treated with single and up to 38% of patients treated with multiple chemotherapeutic agents. Present medications available for CIPN are the use of opioids, nonsteroidal anti-infammatory agents, and tricyclic antidepressants, which are only marginally efective in treating neuropathic symptoms. In reality, symptom reappears after these drugs are discontinued. The pathogenesis of CIPN has not been sufciently recognized and methods for the prevention and treatment of CIPN remain vulnerable to therapeutic problems. It has witnessed that the present medicines available for the disease ofer only symptomatic relief for the short term and have severe adverse side efects. There is no standard treatment protocol for preventing, reducing, and treating CIPN. Therefore, there is a need to develop curative therapy that can be used to treat this complication. Melittin is the main pharmacological active constituent of honeybee venom and has therapeutic values including in chemotherapeutic-induced peripheral neuropathy. It has been shown that melittin and whole honey bee venom are efective in treating paclitaxel and oxaliplatin-induced peripheral neuropathy. The use of melittin against peripheral neuropathy caused by chemotherapy has been limited despite having strong therapeutic efcacy against the disease. Melittin mediated haemolysis is the key reason to restrict its use. In our study, it is found that α-Crystallin (an eye lens protein) is capable of inhibiting melittin-induced haemolysis which gives hope of using an appropriate combination of melittin and α- rystallin in the treatment of CIPN.The review summarizes the eforts made by diferent research groups to address the concern with melittin in the treatment of chemotherapeutic-induced neuropathy. It also focuses on the possible approaches to overcome melittin-induced haemolysis

Item Type: Article
Uncontrolled Keywords: Chemotherapy; Peripheral neuropathy; Melittin; Haemolysis; α-Crystallin
Subjects: Pharmacy > MCOPS Manipal > Pharmaceutical Biotechnology
Depositing User: KMC Library
Date Deposited: 08 Sep 2021 10:35
Last Modified: 08 Sep 2021 10:35
URI: http://eprints.manipal.edu/id/eprint/157240

Actions (login required)

View Item View Item